Q3 2017 EPS Estimates for TESARO, Inc. (NASDAQ:TSRO) Boosted by Wedbush

TESARO, Inc. (NASDAQ:TSRO) – Equities researchers at Wedbush increased their Q3 2017 earnings estimates for shares of TESARO in a research note issued on Wednesday. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.52) per share for the quarter, up from their prior forecast of ($1.65). Wedbush has a “Outperform” rating and a $168.00 price objective on the stock. Wedbush also issued estimates for TESARO’s Q4 2017 earnings at ($2.32) EPS, FY2017 earnings at ($8.20) EPS, Q1 2018 earnings at ($1.56) EPS, Q2 2018 earnings at ($1.26) EPS, Q3 2018 earnings at ($0.92) EPS, Q4 2018 earnings at ($0.57) EPS, FY2018 earnings at ($4.31) EPS, FY2019 earnings at $1.75 EPS, FY2020 earnings at $8.83 EPS and FY2021 earnings at $14.74 EPS.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the company earned ($1.28) earnings per share. The business’s revenue was down 17.6% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2800945/q3-2017-eps-estimates-for-tesaro-inc-nasdaqtsro-boosted-by-wedbush.html.

A number of other equities analysts have also weighed in on the stock. Robert W. Baird restated a “neutral” rating and issued a $140.00 price objective (down from $155.00) on shares of TESARO in a report on Thursday. Morgan Stanley restated an “overweight” rating and issued a $183.00 price objective on shares of TESARO in a report on Thursday. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Finally, BidaskClub lowered shares of TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and an average target price of $176.35.

TESARO (NASDAQ:TSRO) opened at 110.89 on Friday. The company’s market capitalization is $5.99 billion. The firm’s 50-day moving average price is $131.54 and its 200 day moving average price is $149.39. TESARO has a one year low of $83.26 and a one year high of $192.94.

In other news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 40.50% of the company’s stock.

Several large investors have recently modified their holdings of TSRO. Botty Investors LLC acquired a new stake in shares of TESARO during the second quarter worth about $140,000. Meeder Asset Management Inc. acquired a new stake in shares of TESARO during the first quarter worth about $177,000. Oppenheimer Asset Management Inc. increased its stake in shares of TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter. BB&T Securities LLC acquired a new stake in shares of TESARO during the second quarter worth about $222,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of TESARO during the second quarter worth about $224,000.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.